CIK 0001764013 · Large accelerated filer
Immunovant, Inc.
Sign in to watch- Ticker
- IMVT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832771572
- Phone
- 917-410-3120
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Former names
- Health Sciences Acquisitions Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,030,805
- in 10 filings, $173K under 10b5-1 plans
Net −$1,030,805. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-15 | Salzmann Peter Chief Executive Officer | Sale | −8,352 | $23.81 | $199K | 964,640 |
| 2025-01-15 | Salzmann Peter Chief Executive Officer | Sale | −415 | $24.19 | $10K | 964,225 |
| 2025-01-13 | Roivant Sciences Ltd. Director | Purchase | +16,845,010 | $20.00 | $336.9M | 96,650,341 |
| 2025-01-08 | Barnett Eva Renee Chief Financial Officer | Sale | −4,105 | $24.10 | $99K | 327,064 |
| 2025-01-08 | Salzmann Peter Chief Executive Officer | Sale | −5,105 | $24.10 | $123K | 972,992 |
| 2024-12-16 | Van Tuyl Christopher Chief Legal Officer | Grant or award | +109,956 | 109,956 | ||
| 2024-12-16 | Van Tuyl Christopher Chief Legal Officer | Grant or award · Stock Option (right to buy) | +137,446 | 137,446 | ||
| 2024-12-02 | Pande Atul Director | Sale 10b5-1 | −7,750 | $28.54 | $221K | 86,663 |
| 2024-12-02 | Hughes Douglas J. Director | Sale 10b5-1 | −5,425 | $28.54 | $155K | 119,585 |
| 2024-11-20 | Levine Mark S. Chief Legal Officer | Sale | −3,650 | $25.45 | $93K | 319,228 |
| 2024-11-20 | Macias William L. Chief Medical Officer | Sale | −3,353 | $25.45 | $85K | 361,791 |
Page 10 of 10 · 191 trades